These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 17121910

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of vascular endothelial growth factor-C and -D on osteoclast differentiation and function in human peripheral blood mononuclear cells.
    Motokawa M, Tsuka N, Kaku M, Kawata T, Fujita T, Ohtani J, Matsuda Y, Terao A, Tanne K.
    Arch Oral Biol; 2013 Jan; 58(1):35-41. PubMed ID: 22771550
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
    Paniagua RT, Chang A, Mariano MM, Stein EA, Wang Q, Lindstrom TM, Sharpe O, Roscow C, Ho PP, Lee DM, Robinson WH.
    Arthritis Res Ther; 2010 Jan; 12(1):R32. PubMed ID: 20181277
    [Abstract] [Full Text] [Related]

  • 26. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
    Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM.
    Clin Cancer Res; 2009 Jun 01; 15(11):3751-9. PubMed ID: 19470728
    [Abstract] [Full Text] [Related]

  • 27. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.
    Granholm S, Lundberg P, Lerner UH.
    J Endocrinol; 2007 Dec 01; 195(3):415-27. PubMed ID: 18000304
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Role of c-Src in cellular events associated with colony-stimulating factor-1-induced spreading in osteoclasts.
    Insogna K, Tanaka S, Neff L, Horne W, Levy J, Baron R.
    Mol Reprod Dev; 1997 Jan 01; 46(1):104-8. PubMed ID: 8981371
    [Abstract] [Full Text] [Related]

  • 30. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
    Kitami S, Tanaka H, Kawato T, Tanabe N, Katono-Tani T, Zhang F, Suzuki N, Yonehara Y, Maeno M.
    Biochimie; 2010 Apr 01; 92(4):398-404. PubMed ID: 20045440
    [Abstract] [Full Text] [Related]

  • 31. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP.
    Mol Cancer Ther; 2010 Jun 01; 9(6):1629-37. PubMed ID: 20484016
    [Abstract] [Full Text] [Related]

  • 32. Engineering a monomeric variant of macrophage colony-stimulating factor (M-CSF) that antagonizes the c-FMS receptor.
    Zur Y, Rosenfeld L, Bakhman A, Ilic S, Hayun H, Shahar A, Akabayov B, Kosloff M, Levaot N, Papo N.
    Biochem J; 2017 Jul 20; 474(15):2601-2617. PubMed ID: 28655719
    [Abstract] [Full Text] [Related]

  • 33. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U, Patel K, Rosol TJ, Ostrowski MC.
    J Bone Miner Res; 2004 Aug 20; 19(8):1339-48. PubMed ID: 15231022
    [Abstract] [Full Text] [Related]

  • 34. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation.
    Li J, Feng W, Lu H, Wei Y, Ma S, Wei L, Liu Q, Zhao J, Wei Q, Yao J.
    J Cell Physiol; 2019 Aug 20; 234(8):12663-12675. PubMed ID: 30536376
    [Abstract] [Full Text] [Related]

  • 35. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.
    J Cell Physiol; 2009 Dec 20; 221(3):618-28. PubMed ID: 19653230
    [Abstract] [Full Text] [Related]

  • 36. An anti-c-Fms antibody inhibits orthodontic tooth movement.
    Kitaura H, Yoshimatsu M, Fujimura Y, Eguchi T, Kohara H, Yamaguchi A, Yoshida N.
    J Dent Res; 2008 Apr 20; 87(4):396-400. PubMed ID: 18362327
    [Abstract] [Full Text] [Related]

  • 37. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages.
    Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Tatamiya M, Nakao N, Yoshida N, Nakayama K.
    Immunol Lett; 2003 Sep 08; 88(3):193-8. PubMed ID: 12941478
    [Abstract] [Full Text] [Related]

  • 38. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, Nakamura K, Kawaguchi H.
    J Bone Miner Res; 2001 Nov 08; 16(11):2074-81. PubMed ID: 11697804
    [Abstract] [Full Text] [Related]

  • 39. Pentamidine Inhibits Titanium Particle-Induced Osteolysis In Vivo and Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Differentiation In Vitro.
    Ihn HJ, Kim K, Cho HS, Park EK.
    Tissue Eng Regen Med; 2019 Jun 08; 16(3):265-273. PubMed ID: 31205855
    [Abstract] [Full Text] [Related]

  • 40. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.
    Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D.
    J Pathol; 2010 May 08; 221(1):77-86. PubMed ID: 20191615
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.